Provided by Tiger Trade Technology Pte. Ltd.

Allogene Therapeutics Inc.

1.76
+0.03001.73%
Post-market: 1.790.0300+1.70%17:21 EDT
Volume:5.40M
Turnover:9.42M
Market Cap:607.20M
PE:-2.70
High:1.78
Open:1.73
Low:1.70
Close:1.73
52wk High:4.46
52wk Low:1.04
Shares:345.00M
Float Shares:262.00M
Volume Ratio:0.93
T/O Rate:2.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6510
EPS(LYR):-0.8652
ROE:-42.39%
ROA:-22.08%
PB:1.39
PE(LYR):-2.03

Loading ...

Allogene publishes Phase 1 data in Journal of Clinical Oncology

TIPRANKS
·
Jul 15

Allogene Says Phase 1 Trial Shows 31% Response Rate for Allo-316 in Cd70-high Metastatic Kidney Cancer

Reuters
·
Jul 15

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of Allo-316 Highlighting First Durable Remissions Following Allogeneic Car T for Treatment of Metastatic Solid Tumors

THOMSON REUTERS
·
Jul 15

Allogene stockholders approve increase in authorized common shares to 800 million

Reuters
·
Jun 23

Press Release: Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Dow Jones
·
Jun 11

Allogene names Zachary Roberts CEO, succeeding David Chang effective July 1, 2026

Reuters
·
May 29

Allogene Therapeutics - Appoints Zachary Roberts as President and CEO Effective July 1, 2026

THOMSON REUTERS
·
May 29

Allogene Therapeutics Announces Planned CEO Succession

THOMSON REUTERS
·
May 29

Allogene Therapeutics - David Chang to Transition From President and CEO, Will Remain on Board

THOMSON REUTERS
·
May 29

Allogene Therapeutics to present at TD Cowen Oncology Innovation Summit

Reuters
·
May 26

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pharvaris (PHVS) and Allogene Therapeutics (ALLO)

TIPRANKS
·
May 14

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 14

Piper Sandler Sticks to Their Buy Rating for Allogene Therapeutics (ALLO)

TIPRANKS
·
May 14

Allogene Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Allogene Therapeutics ends China cell therapy deal with Overland

Reuters
·
May 14

Allogene Therapeutics Q1 Net Loss Narrows

MT Newswires Live
·
May 14

BRIEF-Allogene Therapeutics - Enters Termination Agreement With Overland Therapeutics On May 12, 2026 - SEC Filing

Reuters
·
May 14

Allogene Therapeutics Inc - No Termination Payments Made in Connection With Termination Agreement - SEC Filing

THOMSON REUTERS
·
May 14

Allogene Therapeutics Inc - Terminates Exclusive License Agreement With Overland Therapeutics Effective May 12, 2026 - SEC Filing

THOMSON REUTERS
·
May 14

Allogene Therapeutics Inc - to Hold About 3% of Overland Equity After Surrendering Portion for No Consideration - SEC Filing

THOMSON REUTERS
·
May 14